Literature DB >> 10408603

Nucleus accumbens dopamine depletions make rats more sensitive to high ratio requirements but do not impair primary food reinforcement.

J E Aberman1, J D Salamone.   

Abstract

It has been suggested that nucleus accumbens dopamine is involved in the process of enabling organisms to overcome work-related response costs. One way of controlling work requirements in operant schedules is to use fixed ratio schedules with different ratio requirements. In the present study, the effects of nucleus accumbens dopamine depletions were assessed using four schedules: fixed ratio 1, 4, 16, and 64. Rats with nucleus accumbens dopamine depletions showed behavioral deficits that were highly dependent upon the ratio value; there were no effects of dopamine depletions on fixed ratio 1 lever pressing, but as ratio value got larger, the impairment became much greater. In a separate experiment, pre-feeding to reduce food motivation was shown to produce a different pattern, such that performance on all ratio schedules was substantially impaired. Thus, aspects of food reinforcement that are involved in fixed ratio 1 performance are highly sensitive to food motivation, but are largely unaffected by nucleus accumbens dopamine depletions. Nevertheless, nucleus accumbens dopamine depletions affected the elasticity of demand for food, and enhanced "ratio strain", i.e. they exacerbated the response-suppressing effects of increasing ratio value.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408603     DOI: 10.1016/s0306-4522(99)00004-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  102 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.

Authors:  Samantha E Yohn; Daniela Alberati; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2017-01-12       Impact factor: 4.530

Review 3.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

Review 4.  Calculating utility: preclinical evidence for cost-benefit analysis by mesolimbic dopamine.

Authors:  Paul E M Phillips; Mark E Walton; Thomas C Jhou
Journal:  Psychopharmacology (Berl)       Date:  2006-11-22       Impact factor: 4.530

Review 5.  Forebrain substrates of reward and motivation.

Authors:  Roy A Wise
Journal:  J Comp Neurol       Date:  2005-12-05       Impact factor: 3.215

Review 6.  The nucleus accumbens as part of a basal ganglia action selection circuit.

Authors:  Saleem M Nicola
Journal:  Psychopharmacology (Berl)       Date:  2006-09-16       Impact factor: 4.530

Review 7.  Opioids for hedonic experience and dopamine to get ready for it.

Authors:  M Flavia Barbano; Martine Cador
Journal:  Psychopharmacology (Berl)       Date:  2006-10-10       Impact factor: 4.530

Review 8.  The nucleus accumbens and Pavlovian reward learning.

Authors:  Jeremy J Day; Regina M Carelli
Journal:  Neuroscientist       Date:  2007-04       Impact factor: 7.519

9.  Modeling operant behavior in the Parkinsonian rat.

Authors:  Irene Avila; Mark P Reilly; Federico Sanabria; Diana Posadas-Sánchez; Claudia L Chavez; Nikhil Banerjee; Peter Killeen; Eddie Castañeda
Journal:  Behav Brain Res       Date:  2008-11-27       Impact factor: 3.332

10.  Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing.

Authors:  Andrew M Farrar; Mariana Pereira; Francisco Velasco; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.